Scios, Cephalon and Cor Therapeutics. all new chemical entities all beat down along the way trading back down near there pre-fda approval levels as markets tried to understand the potential earnings power of new drugs.
this is the second time i have held arna i was in and out the first time around. I don't hold this for "B" alone its arna's drug discovery ie receptor mapping abilities that make this a compelling buy and hold.
what Arena has on the market will be worth more in 5 years than that shot in the eye is today.
think about it capt.